Penny L. Moore

Publications

183

Citations

9.1K

h-index

43

Publishing journals

82

Years of publications

20+

Active since

2007

References

8.8K

Institutions

22

1. Host proteins associated with strong neutralizing SARS-CoV-2 antibody responses in a South African cohort.
   Communications medicine, Year 2026
2. Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
   Nature Communications, Year 2026
3. Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review
   AIDS Research and Therapy, Volume 22, Issue 1, Pages 44-44, Year 2025
4. Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance
   Journal of Virology, Volume 99, Issue 2, Pages e0173024-e0173024, Year 2025
5. Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies.
   Journal of virology, Volume 99, Issue 6, No. e00008-25, Page e0000825, Year 2025
6. Broadly neutralizing antibodies, nonneutralizing antibodies and broadly effector antibodies to prevent HIV transmission?
   AIDS, Volume 39, Issue 7, Pages 918-920, Year 2025
7. Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development
   Cell Host & Microbe, Volume 33, Issue 2, Pages 279-293.e6, Year 2025
8. Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy
   Nature Immunology, Volume 26, Issue 11, Pages 2016-2029, Year 2025
9. Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.
   Nature communications, Volume 16, Issue 1, Page 8876, Year 2025
10. Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women.
    The Journal of antimicrobial chemotherapy, Volume 80, Issue 8, Pages 2135-2144 2135-2144, Year 2025
11. Neutralizing antibody responses over time in a demographically and clinically diverse cohort of individuals recovered from SARS-CoV-2 acquisition in Africa: A cohort study.
    PLOS global public health, Volume 5, Issue 9, Page e0005156, Year 2025
12. Randomised Trial of a Single Dose of Ad26.COV2.S, BNT162b2 or SARS-CoV-2-rS-PN in Previously Vaccinated and Unvaccinated Adults Living with and without HIV in South Africa: Safety and Immunogenicity
    SSRN Electronic Journal, Year 2025
13. SARS-CoV-2 vaccines elicit differential Fc effector functions
    iScience, Volume 28, Issue 8, Pages 113084-113084, Year 2025
14. Mechanistic insights into increased vulnerability to respiratory infections in HIV-Exposed Uninfected Infants.
    The Journal of infectious diseases, Year 2025
15. Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume 80, Issue Supplement_1, Pages S57-S65 S57-S65, Year 2025
16. Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults
    The Journal of infectious diseases, Volume 232, Issue 4, Pages e565-e570 e565-e570, Year 2025
17. Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge
    Viruses, Volume 17, Issue 2, Pages 277-277, Year 2025
18. Africa is an Essential Partner in the Research and Development of an HIV Vaccine.
    Current HIV research, Volume 23, Year 2025
19. Cell-free RNA reveals host and microbial correlates of broadly neutralizing antibody development against HIV
    bioRxiv (Cold Spring Harbor Laboratory), Year 2025
20. SARS-CoV-2 correlates of protection from infection against variants of concern
    Nature Network Boston, Volume 30, Issue 10, Pages 2805-2812, Year 2024

No publications in the index yet.